Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib-associated hypertension clinical aspects study
NL-OMON31245Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of sunitinib in renal cell carcinoma (RCC) and gastrointestinal stromal tumor (GIST), sponsored by Erasmus MC. Primary endpoints: Clinically relevant treatment-induced blood pressure increase, WHO hypertension stage classification change and 2 more. Started Jan 2008; status: active, not recruiting.
02
Drugs
sunitinib
03
Conditions
renal cell carcinoma (RCC)gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NL-OMON31245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31245.